Entries by Bastian Arlt

Patent on solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract

Abstract The patent “Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract” (US20250127722A1 [1]) presents a novel pharmaceutical formulation. It uses microcrystalline cellulose pellets, called CELLETS®, as inert starter cores for controlled-release drug delivery systems. Moreover, these CELLETS® act as a stable foundation, ensuring uniform layering of active pharmaceutical ingredients […]

6. May 2025 by
, ,

Real-time monitoring of multiparticulate coating processes at industrial-scale using ultra-high-resolution optical coherence tomography

Real-time monitoring of multiparticulate coating processes at industrial-scale is a critical demand for continuous and batch-wise process technologies. A combination with ultra-high-resolution optical coherence tomography is indeed a brilliant idea. Results were recently published by Wolfgang et al. [1] Previous challenges in PAT of multiparticulate systems This study presents a significant advancement in pharmaceutical process […]

14. April 2025 by
,

Patent on oral formulations of a Pyridinone derivate

Abstract This patent describes an oral formulation designed to deliver a drug (a Pyridinone derivative) specifically to the small intestine. The formulation contains coated granules, pellets, beads, minicapsules, or minitablets. Each particle includes a core material and an enteric coating polymer, which ensures targeted drug release. Moreover, the patent covers the preparation method and its […]

17. February 2025 by
, , , , , ,

Patent on enteric-coated particles containing lactoferrin

Abstract The present invention generally relates to enteric-coated particles containing lactoferrin. More specifically, the present invention provides an enteric-coated particle comprising (or consisting essentially of): a) a core comprising (or consisting essentially of) an inert core-forming material selected from cellulose polymer, sugar, sugar alcohol, starch and carnauba wax; b) a first coating layer substantially covering […]

17. February 2025 by
, , , ,

Revealing the physical restrictions of caecal influx in broilers through the use of solid and soluble markers

Abstract A promising strategy to support broiler health and performance in a sustainable way is the enhancement of microbial fibre fermentation in broilers. This fermentation mainly occurs in the caeca, but the actual particle size range that allows caecal influx has not yet been described. This study aimed to understand the physical limitations of caecal […]

20. January 2025 by

Conclusion of the Blog Series: Innovations in Controlled Drug Release

Over the past few weeks, we have explored the fascinating world of patents related to controlled and modified drug release through our eight-part blog series. This journey has taken us from the extended release of pyridostigmine and atomoxetine to the innovative formulations of gamma-hydroxybutyrate. 🚀💊 Each entry provided valuable insights into the advancements in Cellets […]

7. January 2025 by
,

Patent on pharmaceutical compositions and methods for treating hyperhidrosis

The patent application US20240350420A1 focuses on pharmaceutical formulations and methods for treating conditions such as hyperhidrosis, which causes excessive sweating. It details the development of modified-release compositions using Pilocarpine HCl, a muscarinic agonist. These formulations aim to optimize drug delivery by using various release mechanisms, including immediate, delayed, or sustained release. Notably, the innovations include […]

21. November 2024 by
,

Patent on gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state

Patents US20240350437A1 and US20240350438A1 – Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state – cover pharmaceutical compositions and systems that deliver oral drugs in a controlled and consistent way. The invention tackles challenges in delayed or multi-stage drug release. This is especially important for active pharmaceutical ingredients (APIs) with complex absorption profiles or sensitivity to […]

21. November 2024 by

What does AI say about CELLETS?

Did you ever wonder, what AI engines say about CELLETS? Artificial Intelligence engines answers by example of ChatGPT, version GPT-4o executed on Oct 12, 2024 is breath-taking. For better visibility, we shortened some answers and indicated that in the text not loosing seriousness :). You: why are CELLETS so beautiful? ChatGPT: CELLETS are beautiful because […]

13. November 2024 by